Cardiff Oncology (NASDAQ:CRDF) Price Target Raised to $10.00 at Piper Sandler

Cardiff Oncology (NASDAQ:CRDF) had its target price upped by equities research analysts at Piper Sandler from $7.00 to $10.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s price target would suggest a potential upside of 155.10% from the company’s current price.

CRDF has been the subject of several other reports. HC Wainwright lowered their price target on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating for the company in a report on Friday, November 8th. Craig Hallum assumed coverage on Cardiff Oncology in a research report on Friday, September 6th. They issued a “buy” rating and a $8.00 target price for the company.

Cardiff Oncology Price Performance

CRDF stock opened at $3.92 on Friday. The stock has a market cap of $200.43 million, a price-to-earnings ratio of -4.17 and a beta of 1.89. The company has a 50 day simple moving average of $2.89 and a 200 day simple moving average of $2.61. Cardiff Oncology has a 1 year low of $1.27 and a 1 year high of $6.42.

Insider Activity

In related news, Director Gary W. Pace purchased 350,115 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was bought at an average price of $2.60 per share, with a total value of $910,299.00. Following the completion of the purchase, the director now owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This represents a 50.18 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 7.80% of the company’s stock.

Institutional Trading of Cardiff Oncology

Several institutional investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. raised its holdings in Cardiff Oncology by 380.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock worth $2,699,000 after purchasing an additional 962,940 shares during the last quarter. GSA Capital Partners LLP increased its position in shares of Cardiff Oncology by 432.7% during the third quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock worth $498,000 after buying an additional 151,613 shares during the period. Bank of New York Mellon Corp bought a new position in Cardiff Oncology during the second quarter worth $256,000. XTX Topco Ltd acquired a new position in Cardiff Oncology in the second quarter valued at $185,000. Finally, Renaissance Technologies LLC boosted its position in Cardiff Oncology by 82.9% during the second quarter. Renaissance Technologies LLC now owns 157,490 shares of the company’s stock valued at $350,000 after acquiring an additional 71,390 shares during the last quarter. 16.29% of the stock is currently owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.